DOCSLIB.ORG

Moderate-To-Severe Psoriasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Moderate-To-Severe Psoriasis Winter 2012 Special supplement MODERATE-TO-SEVERE PSORIASIS 1.5 CPD credits Prescribing information can be Initiated, funded and found on the inside back cover reviewed by CONTENTS AND INTRODUCTION INTRODUCTION OPINION Psoriasis is a chronic skin condition that can 3 The role of GPs in the management of have a marked physical and psychological moderate-to-severe psoriasis impact on those affected. While most patients Dr Brian Malcolm have mild disease that can be managed in primary care, those with moderate-to-severe FEATURE psoriasis require referral for specialist inter- 4 Diagnosis and management of vention and access to therapy such as biologics. moderate-to-severe psoriasis Biologics are an option for patients who have Dr Rebecca Ellard and Dr Anshoo Sahota failed to respond to standard systemic ther- apy or in those for whom systemic therapy is FEATURE unsuitable. The scope of this supplement is to 6 Achieving long-term control of enhance the understanding of biologics. moderate-to-severe psoriasis Dr Brian Malcolm provides his opinion Dr Amy Foulkes and Dr Richard Warren on the role of the GP in the management of moderate -to-severe psoriasis. CASE STUDY Dr Rebecca Ellard and Dr Anshoo Sahota 8 A patient treated with ustekinumab discuss the key elements of the diagnosis and Dr Alia Ahmed and Dr Anthony Bewley management of moderate-to-severe psoriasis. Dr Amy Foulkes and Dr Richard Warren OPINION focus on long-term control of psoriasis. 9 NICE guideline on the assessment and Dr Alia Ahmed and Dr Anthony Bewley management of psoriasis present a case of a patient who was success- Dr David Chandler and Dr Anthony fully treated with biologics. Bewley Dr David Chandler and Dr Anthony Bewley provide a summary of the recently published MANAGEMENT ALGORITHM NICE guideline on psoriasis. 10 Diagnosis and management of Dr Justine Kluk, Dr Sandy McBride and moderate-to-severe psoriasis Professor Malcolm Rustin present a manage- Dr Justine Kluk, Dr Shantini Rice, Dr ment algorithm to aid the diagnosis, treatment Sandy McBride and Professor Malcolm and referral of patients with moderate-to- Rustin severe psoriasis Dr Paula Hensler, Editor, MIMS Dermatology Published by Haymarket Medical, 174 Hammersmith Road, London W6 7JP. Senior project editor: Joanne Taylor; Managing editor: Hannah Cottle; Editor of MIMS Dermatology: Paula Hensler; Producer: Stephanie Jackson; Commercial director: Sandie Pears; Project manager: Lindsay Aldridge; Group art editor: Pauline Lock; Deputy production manager: Lucy Flatman; Head of delivery: Katie McCormack; Senior commercial director: Clair McHale; Medical director: Robert Brines; Medical education director: Richard Yarwood; Director: Jenny Gowans. The views expressed in this publication are those of the authors and not necessarily those of Haymarket Medical or Janssen. Readers are advised to make their own further enquiries of manufacturers or specialists in relation to particular drugs, treatments or advice. The publishers and printers cannot accept liability for errors or omissions. No part of this publication may be reproduced in any form without the written permission of the publisher, application for which should be made to the publisher. ©2013 Haymarket Medical Media Ltd. Date of preparation: November 2012 (revised April 2013); Haymarket is certified by BSI to PHGB/STE/1112/0755b environmental standard ISO14001 2 OPINION The role of GPs in the management of moderate-to-severe psoriasis GPs have a pivotal role in managing under specialist care, the GP still has a pivotal this condition, says Dr Brian Malcolm. role in repeat prescribing and shared-care plans. Psoriasis is common, affecting approximately SECOND-LINE TREATMENTS 2% of the UK population.1 Such prevalence GPs should have understanding of the patient’s demands that a GP should have an up-to-date individual needs. Furthermore, there should knowledge of this condition, specifically the be an awareness of commonly used second- potential triggers, the treatments available and line drugs and their implications, for example, when to refer patients to secondary care. family planning issues with the use of retin- oids,4 alcohol intake with methotrexate,4 renal PHYSICAL AND PSYCHOLOGICAL DISTRESS function, hypertension and a history of cancer Psoriasis can be very distressing.2 Patients can with ciclosporin4 and a past history of infections, be significantly disabled by plantopalmar pus- particularly TB, and cancer with biologics.6 tular psoriasis, severe scalp psoriasis, fissuring hyperkeratotic psoriasis of the hands, or rarely, REFERRAL TO SECONDARY CARE acropustulosis. Genital involvement can also Referral should be considered when there is diag- lead to high levels of sexual distress.3 GPs are nostic doubt; when topical treatments have failed; well placed to offer support and manage patient in extensive disease and where there are difficult expectations about treatment outcomes. treatment sites. Erythrodermic or generalised pustular psoriasis also warrant referral, as does RECOGNISING TRIGGERS severe arthropathy. GPs have an important role GPs should understand the pathogenesis of in writing relevant and precise referral letters. the psoriasis to avoid exacerbations with the Even when a patient requires specialist care, use of prescribed drugs known to potentially there is potential for a knowledgeable GP to con- worsen psoriasis. These include lithium, anti- tribute to a holistic management approach. malarials and beta-blockers.4 GPs can also offer Dr Brian Malcolm is associate specialist, advice regarding exacerbating lifestyle factors GP principal and GPSI in dermatology in such as alcohol, stress and smoking,4 especially Barnstaple, Devon as there is a growing recognition that psoriasis is an independent risk factor for cardiovascu- REFERENCES lar disease.5 1. Eedy DJ, Griffiths CEM, Chalmers RJG et al. Care of patients with psoriasis: an audit of UK services in secondary care. Br J Dermatol 2009; 160:557–64. TREATMENT KNOWLEDGE 2. Krueger G, Koo J, Lebwohi M et al. The impact of psoriasis on It is important that GPs have a good understand- quality of life: Results of a 1998 National Psoriasis Foundation patient memebership survey. Arch Dermatol 2001 :137:280-4 ing of topical treatments. GPs must also be aware 3. Meeuwis KA, de Hullu JA, van de Nieuwenhof HP et al. that certain topical treatments, particularly ster- Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol 2011; 164:1247-55. oids, may have systemic effects if they are used 4. Menter A, Griffiths CEM. Current and future management of long term.4 Furthermore, the usefulness of psoriasis. Lancet 2007;370:272-84. 5. Ahlehoff O. Psoriasis and cardiovascular disease: simple emollients to keep skin hydrated should epidemiological studies. Dan Med Bull. 2011; 58:B4347. 4 never be underestimated. Even if a patient is 6. MIMS. November 2012. 3 FEATURE Diagnosis and management of moderate-to-severe psoriasis Management should include early and continual assessment from first presentation through to specialist care, write Dr Rebecca Ellard and Dr Anshoo Sahota iStockphoto/ThinkStock Psoriasis is a chronic disease that affects approxi- mately 1-3% of the population,1 with or without psoriatic arthritis. Patients typically present with ‘unsightly’ lesions which are sometimes itchy; for many there is no identifiable cause. Patients present with lesions Psoriasis can have a profound effect on quality of life and is also associated with cardiovascu- with topical therapy.4 More extensive disease lar disease.2 Recent NICE guidance states that (>10% body affected or PASI score >12) usually management should include early and continual needs specialist input. assessment of psoriasis from first presenta- Functional severity can be measured with tion in primary care through to specialist care. quality-of-life tools such as the Dermatology The guidance focuses on disease severity, phys- Life Quality Index (DLQI).5 Psychological ical and psychological effect, assessment for morbidity is not well represented with these referral and treatment choice.2 tools, but can be an important marker for dis- ease impact. NICE guidelines suggest assessing ASSESSMENT OF PSORIASIS impact on daily living, ability to cope with the Various tools can be used to measure physi- treatment regimen, change in mood and impact cal severity or functional severity of psoriasis. on family or carers.2 Physical severity is categorised as clear, mild, severe or very severe, as outlined in the STEPWISE APPROACH TO MANAGEMENT Physicians’ Global Assessment (PGA) or more Management of chronic illness such as psoria- precisely with the Psoriasis Area and Severity sis should include physical and psychological Index (PASI).3 Doctors should also note when aspects.2 It is helpful to manage expectations at nails, face, scalp or genitals are affected as these an early stage and allow the patient control over are particularly difficult to treat, along with their treatment, particularly with topical ther- symptoms or signs of psoriatic arthritis. apy. There is often the need to combine topical The PASI divides the body into head, arms, and systemic treatments. trunk and legs and notes the amount of redness, The first step is topical treatment including thickness and scale, along with percentage of the daily use of emollients. Patients should be area affected. A score maximum of 72 is given, reassured that almost any emollient is useful and can help assess a patient’s response to treat- even if not prescribed
Load more

Recommended publications
  • Viral Rashes: New and Old Peggy Vernon, RN, MA, CPNP, DCNP, FAANP C5
    Viral Rashes: New and Old Peggy Vernon, RN, MA, CPNP, DCNP, FAANP C5 Disclosures •There are no financial relationships with commercial interests to disclose Viral Rashes: New and Old •Any unlabeled/unapproved uses of drugs or products referenced will be disclosed Peggy Vernon, RN, MA, CPNP, DCNP, FAANP ©Pvernon2021 ©Pvernon2021 Restrictions Objectives • Permission granted to the 2021 National Nurse • Identify a potential sequelae from hand, foot and Practitioner Symposium and its attendees mouth disease • Describe the pattern of distribution and lesion • All rights reserved. No part of this presentation may description of varicella be reproduced, stored, or transmitted in any form or • Identify a precursor of Henoch Schonlein Purpura by any means without written permission of the author •Contact Peggy Vernon at [email protected] ©Pvernon2021 ©Pvernon2021 Viral Exanthems Morbilliform Exanthems •Morbilliform • Measles (rubeola) •Papular-nodular • Rubella •Vesiculobullous • Roseola •Petechial • Erythema Infectiosum •Purpuric • Pityriasis Rosea • Infectious Mono ©Pvernon2021 ©Pvernon2021 1 Viral Rashes: New and Old Peggy Vernon, RN, MA, CPNP, DCNP, FAANP C5 Measles (Rubeola) MEASLES (RUBEOLA) • Prodrome: fever, malaise, cough, DIFFERENTIAL DIAGNOSIS conjunctivitis. Patient appears quite ill •Other morbilliform eruptions: Rubella, • Koplik’s spots: bluish-white erythema infectiosum, pityriasis rosea, elevations on buccal mucosa infectious mono • Exanthem: erythematous •DRUG maculopapular eruption, from scalp to forehead, posterior
    [Show full text]
  • Drug Treatments in Psoriasis
    Drug Treatments in Psoriasis Authors: David Gravette, Pharm.D. Candidate, Harrison School of Pharmacy, Auburn University; Morgan Luger, Pharm.D. Candidate, Harrison School of Pharmacy, Auburn University; Jay Moulton, Pharm.D. Candidate, Harrison School of Pharmacy, Auburn University; Wesley T. Lindsey, Pharm.D., Associate Clinical Professor of Pharmacy Practice, Drug Information and Learning Resource Center, Harrison School of Pharmacy, Auburn University Universal Activity #: 0178-0000-13-108-H01-P | 1.5 contact hours (.15 CEUs) Initial Release Date: November 29, 2013 | Expires: April 1, 2016 Alabama Pharmacy Association | 334.271.4222 | www.aparx.org | [email protected] SPRING 2014: CONTINUING EDUCATION |WWW.APARX.Org 1 EducatiONAL OBJECTIVES After the completion of this activity pharmacists will be able to: • Outline how to diagnose psoriasis. • Describe the different types of psoriasis. • Outline nonpharmacologic and pharmacologic treatments for psoriasis. • Describe research on new biologic drugs to be used for the treatment of psoriasis as well as alternative FDA uses for approved drugs. INTRODUCTION depression, and even alcoholism which decreases their quality of Psoriasis is a common immune modulated inflammatory life. It is uncertain why these diseases coincide with one another, disease affecting nearly 17 million people in North America and but it is hypothesized that the chronic inflammatory nature of Europe, which is approximately 2% of the population. The highest psoriasis is the underlying problem. frequencies occur in Caucasians
    [Show full text]
  • The Management of Psoriasis in Adults
    DORSET MEDICINES ADVISORY GROUP THE MANAGEMENT OF PSORIASIS IN ADULTS Psoriasis is a common, genetically determined, inflammatory and proliferative disorder of the skin, the most characteristic lesions consisting of chronic, sharply demarcated, dull-red, scaly plaques, particularly on the extensor prominences and in the scalp. Self-care advice Many people's psoriasis symptoms start or become worse because of a certain event, known as a trigger. Common triggers include: • an injury to skin such as a cut, scrape, insect bite or sunburn (this is known as the Koebner response) • drinking excessive amounts of alcohol • smoking • stress • hormonal changes, particularly in women (for example during puberty and the menopause) • certain medicines such as lithium, some antimalarial medicines, anti-inflammatory medicines including ibuprofen, ACE inhibitors (used to treat high blood pressure) and beta blockers (used to treat congestive heart failure) • throat infections - in some people, usually children and young adults, a form of psoriasis called guttate psoriasis (which causes smaller pink patches, often without a lot of scaling) develops after a streptococcal throat infection, although most people who have streptococcal throat infections do not develop psoriasis • other immune disorders, such as HIV, which cause psoriasis to flare up or to appear for the first time Advice for patients can be found here Management pathway For people with any type of psoriasis assess: • disease severity • the impact of disease on physical, psychological and social wellbeing • whether they have psoriatic arthritis • the presence of comorbidities. • Consider using the Dermatology quality of life assessment: www.pcds.org.uk/p/quality-of-life Assess the severity and impact of any type of psoriasis: • at first presentation • before referral for specialist advice and at each referral point in the treatment pathway • to evaluate the efficacy of interventions.
    [Show full text]
  • Pityriasis Rosea
    BMJ 2015;351:h5233 doi: 10.1136/bmj.h5233 (Published 29 October 2015) Page 1 of 6 Practice PRACTICE PRACTICE POINTER Pityriasis rosea Samantha Eisman consultant dermatologist, Rodney Sinclair professor in dermatology Sinclair Dermatology, Melbourne, VIC, 3002, Australia Pityriasis rosea is an acute exanthem that may cause patients great anxiety but is self limiting and resolves within one to three How does pityriasis rosea present? months.1 It is a distinctive erythematous oval scaly eruption of Pityriasis rosea begins in 40-76% of patients with a single herald the trunk and limbs, with minimal constitutional symptoms. patch—an asymptomatic thin oval scaly plaque often on the What causes pityriasis rosea? trunk (fig 1⇓).7 Multiple herald patches may also occur.8 The patch is usually well demarcated, 2-4 cm in diameter, The cause of pityriasis rosea is uncertain but epidemiological erythematous, salmon coloured, or hyperpigmented. A fine (seasonal variation and clustering in communities) and clinical collarette of scale is attached to the periphery of the plaque with features suggest an infective agent. Light and electron its free edge extending internally. Within days to three weeks microscopy findings suggest infection with human herpesviruses 2 the second phase begins—the appearance of numerous smaller 6 and 7 (HHV-6/7). These viral antigens have been detected lesions, which are similar in configuration but occur along the in skin lesions by immunohistochemistry and their DNA has lines of cleavage of the trunk (Christmas tree pattern; figs 2⇓ been isolated from non-lesional skin, peripheral blood 3 and 3⇓). The rash typically lasts five weeks; it resolves within mononuclear cells, serum, and saliva samples.
    [Show full text]
  • Aafp Fmx 2020
    Challenging Pediatric Rashes Richard P. Usatine, MD, FAAFP Professor, Family and Community Medicine Professor, Dermatology and Cutaneous Surgery University of Texas Health, San Antonio 1 ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations. The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material 2 might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP. 2 1 Disclosure Statement It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflicts of interest. If conflicts are identified, they are resolved prior to confirmation of participation.
    [Show full text]
  • Quick Reference Guide Therapy Intra- Responder Non-Responder DMARD Articular Responder Non-Responder Steroids DLQI >5
    PSORIASIS AND PSORIATIC ARTHRITIS CARE PATHWAY PSORIASIS PATIENT PRESENTING IN PRIMARY CARE Articular symptoms Assess severity suggestive of PsA? Erythrodermic or DERMATOLOGY DEPARTMENT Assess vascular risk pustular psoriasis: YES Assess comorbidities Emergency referral is Refer to psychology as indicated appropriate RHEUMATOLOGY DEPARTMENT Confirm diagnosis Provide patient information Document severity Assess comorbidities Refer to AHPs as appropriate Topical therapy Consider involving Confirm diagnosis rheumatology Document severity Assess comorbidities Refer to AHPs as appropriate Topical Topical Diagnosis and management of psoriasis Photo- Systemic Consider involving dermatology Re-assess in 4-6 weeks outpatient inpatient therapy therapy and psoriatic arthritis in adults DLQI ≤5: therapy therapy 121 Second topical Quick Reference Guide therapy Intra- Responder Non-responder DMARD articular Responder Non-responder steroids DLQI >5 Annual review in primary care Biologic Responder Non-responder • document severity Continue treatment treatment • assess comorbidities: vascular risk, articular symptoms, Shared care depression with GP Biologic Continue • optimise topical treatment. treatment treatment Key: (abbreviations) Shared care AHP allied health professional with GP DLQI Dermatology Life Quality Index DMARD disease modifying anti-rheumatic drug PsA psoriatic arthritis ONLINE RESOURCES This Quick Reference Guide provides a summary of the main recommendations in SIGN 121 Diagnosis and management of (PASI) Psoriasis Area and Severity Index Calculator psoriasis and psoriatic arthritis in adults. http://pasi.corti.li/ British Association of Dermatologists Biologic Interventions Register Recommendations are graded A B C D to indicate the strength (BADBIR) www.badbir.org of the supporting evidence. Psoriasis Association Good practice points are provided where the guideline www.psoriasis-association.org.uk development group wishes to highlight specific aspects of Psoriasis and Psoriatic Arthritis Alliance (PAPAA) accepted clinical practice.
    [Show full text]
  • “I Have a Rash!”
    “I have a rash!” Kim Sanders PA-C Assistant Professor OHSU Dermatology Disclosures • none Goals: • Compare and contrast some common dermatological conditions • Present some less common conditions that are mimickers of common conditions Case #1: • 25 year old healthy female with a new rash x 4 weeks. • It is mildly itchy and covers most of her trunk • She is feeling well currently, but notes a cold and sore throat prior to the eruption of the rash that has resolved without treatment • She recently started a new job that includes public speaking. Due to her anxiety over this she has started prn propranolol. • No other medications or chronic medical conditions • Family history significant for an uncle that had “skin problems”, no details known • Social history: she is single and actively dating. Does admit to recent unprotected intercourse with more than one male partner. Clinical exam: Differential diagnosis: • Guttate psoriasis • Syphilis • Pityriasis rosea • Extensive tinea corporis A little more history… • She does feel that the rash started with one plaque on her right anterior hip about a week before it exploded all over her body Diagnosis: • Pityriasis rosea! • Should you get an RPR? Treatment: • Topical steroids if needed to help with itching • Consider biopsy if does not resolve within 12 weeks Considerations: • What if she had strep throat prior to the eruption of the rash? • What if she had erythematous macules on her palms? • What if you saw her the first week, when she only had one lesion? • Is the addition of propranolol important? Case #2 • 40 year old female with new onset hair loss first noticed by her hair dresser, however it is progressing quickly.
    [Show full text]
  • Pediatric Psoriasis
    Pediatric Papulosquamous and Eczematous Disorders St. John’s Episcopal Hospital Program Director- Dr. Suzanne Sirota-Rozenberg Dr. Brett Dolgin, DO Dr. Asma Ahmed, DO Dr. Anna Slobodskya, DO Dr. Stephanie Lasky, DO Dr. Louis Siegel, DO Dr. Evelyn Gordon, DO Dr. Vanita Chand, DO Pediatric Psoriasis Epidemiology • Psoriasis can first appear at any age, from infancy to the eighth decade of life • The prevalence of psoriasis in children ages 0 to 18 years old is 1% with an incidence of 40.8 per 100,000 ppl • ~ 75% have onset before 40 years of age What causes psoriasis? • Multifactorial • Genetics – HLA associations (Cw6, B13, B17, B57, B27, DR7) • Abnormal T cell activation – Th1, Th17 with increased cytokines IL 1, 2, 12, 17, 23, IFN-gamma, TNF-alpha • External triggers: – Injury (Koebner phenomenon) – medications (lithium, IFNs, β-blockers, antimalarials, rapid taper of systemic corticosteroids) – infections (particularly streptococcal tonsillitis). Pediatric Psoriasis Types: • Acute Guttate Psoriasis – Small erythematous plaques occurring after infection (MOST common in children) • 40% of patients with guttate psoriasis will progress to develop plaque type psoriasis • Chronic plaque Psoriasis – erythematous plaques with scaling • Flexural Psoriasis – Erythematous areas between skin folds • Scalp Psoriasis – Thick scale found on scalp • Nail Psoriasis – Nail dystrophy • Erythrodermic Psoriasis– Severe erythema covering all or most of the body • Pustular Psoriasis – Acutely arising pustules • Photosensitive Psoriasis – Seen in areas of sun
    [Show full text]
  • Neutrophilic Dermatoses – Part II
    195 EDUCAÇÃO MÉDICA CONTINUADA L Dermatoses neutrofílicas – Parte II * Neutrophilic dermatoses – Part II Fernanda Razera1 Gislaine Silveira Olm2 Renan Rangel Bonamigo3 Resumo: Neste artigo são abordadas as dermatoses neutrofílicas, complementando o artigo anterior (parte I). São apresentadas e comentadas as seguintes dermatoses: pustulose subcórnea de Sneddon- Wilkinson, dermatite crural pustulosa e atrófica, pustulose exantemática generalizada aguda, acroder- matite contínua de Hallopeau, pustulose palmoplantar, acropustulose infantil, bacteride pustular de Andrews e foliculite pustulosa eosinofílica. Uma breve revisão das dermatoses neutrofílicas em pacientes pediátricos também é realizada. Palavras-chave: Dermatopatias; Infiltração de neutrófilos; Pediatria Abstract: This article addresses neutrophilic dermatoses, thus complementing the previous article (part I). The following dermatoses are introduced and discussed: subcorneal pustular dermatosis (Sneddon-Wilkinson disease), dermatitis cruris pustulosa et atrophicans, acute generalized exanthema- tous pustulosis, continuous Hallopeau acrodermatitis, palmoplantar pustulosis, infantile acropustulo- sis, Andrews' pustular bacteride and eosinophilic pustular folliculitis. A brief review of neutrophilic dermatoses in pediatric patients is also conducted. Keywords: Neutrophil infiltration; Pediatrics; Skin diseases PUSTULOSE SUBCÓRNEA DE SNEDDON- WILKINSON A pustulose subcórnea de Sneddon-Wilkinson necrose tumoral alfa, interleucina-8, fração comple- ou dermatose pustular subcórnea ou doença
    [Show full text]
  • Home Phototherapy Order Form
    Physician’s Written Order for Home Phototherapy Fax to: 605-322-2475 or Email: [email protected] This form is a Prescription and Statement of Medical Necessity for Daavlin home phototherapy products Rx used for the treatment of skin conditions such as psoriasis. All fields required for insurance approval. First Name _______________________ Last Name _________________________ DOB ____/____/____ Gender: M F Address _____________________________________________ City_________________________ State_____ Zip__________ Patient Info: Patient Phone #________________________________ Alt Phone # or Email _______________________________________________ HCPCs: Product and Description: Physician Name ___________________________________ DermaPal: Hand-held treatment wand for scalp, Practice __________________________________________ E0691 spot treatment or travel. Includes comb attachment. NPI# ______________________________________________ E0691 1 Series: Small, light-weight panel for hands, face, Address _________________________________________ feet, elbows, or any other localized treatment area. City ______________________ State ____ Zip _________ 7 Series 8 Lamp: Six foot tall, multi-directional unit Info: Physician Prescribing Phone (____)______________*Fax (____)______________ Home Phototherapy Product: Home Phototherapy E0694 for large areas and/or full body treatment. * IMPORTANT: We will use this fax number to fax the Prescriber’s Dosing Guide ICD-10 Code: Description: ICD-10 Code Estimated Duration of Need: ___ Months (
    [Show full text]
  • Psoriasis Pathogenesis and Treatment
    International Journal of Molecular Sciences Review Psoriasis Pathogenesis and Treatment AdrianaReview Rendon and Knut Schäkel * DepartmentPsoriasis of Dermatology, Pathogenesis Heidelberg University, and 69120 Treatment Heidelberg, Germany; [email protected] * Correspondence: [email protected] Adriana Rendon and Knut Schäkel * Received:Department 25 February of Dermatology, 2019; Accepted: Heidelberg 18 March University, 2019; Published:69120 Heidelberg, 23 March Germany 2019; [email protected] Abstract:* Correspondence:Research on [email protected] psoriasis pathogenesis has largely increased knowledge on skin biology in general.Received: In the 25 past February 15 years, 2019; Accepted: breakthroughs 18 March in2019 the; Published understanding: 23 March of2019 the pathogenesis of psoriasis have been translated into targeted and highly effective therapies providing fundamental insights into Abstract: Research on psoriasis pathogenesis has largely increased knowledge on skin biology in the pathogenesis of chronic inflammatory diseases with a dominant IL-23/Th17 axis. This review general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of psoriasis discusses the mechanisms involved in the initiation and development of the disease, as well as have been translated into targeted and highly effective therapies providing fundamental insights the therapeuticinto the pathogenesisoptions that of have chronic arisen inflammatory from the dissection diseases with of the a inflammatorydominant IL-23 psoriatic/Th17 axis. pathways. This Our discussionreview discusses begins the by mechanisms addressing involved the inflammatory in the initiation pathways and development and key cellof the types disease, initiating as well and perpetuatingas the therapeutic psoriatic inflammation. options that have Next, arisen we from describe the thedissection role of of genetics, the inflammatory associated psoriatic epigenetic mechanisms,pathways.
    [Show full text]
  • Papulosquamous Disorders (Psoriasis, Lichen Planus
    PAPULOSQUAMOUS DISORDERS (PSORIASIS, LICHEN PLANUS & PITYRIASIS ROSEA) Objective of the lecture: • To know the definition of papulosquamous pattern. • To know the group of diseases known as papulosquamous diseases. • Psoriasis pathogenesis, clinical presentation, and management. • Lichen planus pathogenesis, clinical presentation, and management. • Pityriasis rosea pathogenesis, clinical presentation, and management. Done by team leader: Ghada Alhadlaq members: Rawan Alwadee & Deena AlNouwaiser. Revised by: Shrooq Alsomali Before you start.. CHECK THE EDITING FILE Sources: doctor’s slides and notes + Group B teamwork [ Color index: Important|doctor notes|Extra] Papulosquamous diseases: • The term squamous refers to scaling that represents thick Stratum Corneum and thus implies an abnormal keratinization process. - Keratinization is the differentiation of basal keratinocytes. - The basal keratinocytes as they move upward, they accumulate keratin inside them & their organelles totally die. • Papulosquamous diseases are typically characterized by scaly papules (papule = elevated lesion). • It could be papule or plaque, but the papulosquamous is the reaction pattern of the disease which means a reaction (inflammation) inside the skin (within the epidermis & dermis) to a specific thing that presents itself on the surface of the skin with a certain morphology. • Other disease patterns include psoriasiform, lichenoid, bullous, pustular as well as papulosquamous pattern & each has many differential diagnoses. :)الصدفية( Psoriasis • Chronic non-contagious polygenic multisystem inflammatory disease. • Psoriasis can be triggered by infections, trauma, stress and medications. • The characteristic lesion (classical psoriatic lesion) is a sharply demarcated erythematous scaly plaque that may be localized or generalized. • The natural history follows a chronic course with intermittent remissions. • Has two peaks in age of onset (bi-model age presentation): one at 20-30 years and a second at 40-50.
    [Show full text]